Overactive Bladder Treatment Guidelines

Standard Pharmacologic Options for OAB

• The American Urological Association recommends that all patients must receive behavioral therapies first, including bladder training, fluid management, caffeine reduction, and physical activity, before initiating pharmacotherapy 1
• Bladder training has the strongest evidence base among behavioral interventions 1
• The standard second-line medications—antimuscarinics and β3-adrenoceptor agonists—do not have documented effects on cholesterol metabolism, and mirabegron is typically preferred before antimuscarinics due to lower dementia risk 1
• Mirabegron demonstrates similar efficacy to antimuscarinics with a relatively lower adverse event profile 2, 3
• Oxybutynin extended-release is effective but has a higher anticholinergic burden 1

Critical Safety Screening Required

• Before prescribing antimuscarinics, screen for absolute contraindications, including narrow-angle glaucoma, impaired gastric emptying, history of urinary retention, and concurrent solid oral potassium chloride use 1

Managing Inadequate Response

• If first medication fails, consider switching to an alternative antimuscarinic with better tolerability or switching between drug classes (antimuscarinic to β3-agonist or vice versa) 1, 2, 3, 4
• Combination therapy with solifenacin 5 mg plus mirabegron 25-50 mg is an option for patients refractory to monotherapy, with evidence from SYNERGY and BESIDE trials demonstrating additive efficacy without significant pharmacokinetic interactions 4, 5, 6

Third-Line Options for Refractory Cases

• Intradetrusor onabotulinumtoxinA, peripheral tibial nerve stimulation, and sacral neuromodulation are options for refractory cases, requiring willingness to perform clean intermittent self-catheterization or frequent office visits 4, 5

Common Pitfalls to Avoid

• Do not skip behavioral therapies, as they have excellent safety profiles and should be offered to all patients 1
• Do not abandon antimuscarinic therapy after one failed trial, as patients may respond better to different formulations or alternative agents 2, 3
• Exercise caution in frail elderly patients, as those with mobility deficits, unexplained weight loss, or cognitive deficits may have a lower therapeutic index with OAB medications 2, 3